GHU Paris Psychiatrie et Neurosciences
PEPIT
Boris Chaumette, french laureate of the Ecole de l’INSERM, has defended his MD with a specialty in psychiatry and his PhD in neurobiology in 2016. After a post-doc at McGill University (Montreal-Canada), he has been selected for a competitive position at the University of Paris, with the support of INSERM and the Fondation Bettencourt-Schueller. With this position, he dedicated half of his time to the research on the genetics and epigenetics of psychiatric disorders, at the Institute of Psychiatry and Neuroscience of Paris (INSERM U1266). His scientific work aims to better understand the Gene X Environment interactions during the emergence of psychosis in adolescence. Since 2019, he is in charge of the Center for Rare Psychiatric Disorders at the GHU Paris Psychiatrie et Neurosciences (Sainte-Anne hospital in Paris). This Center performs clinical genetic assessments and provides therapeutic advice for the management of patients with rare genetic conditions and psychiatric symptoms. Boris Chaumette is the vice-chair of the European COST Action to Enhance Psychiatric Genetic Counselling, Testing, and Training in Europe (EnGagE network, funded by the EU Horizon 2020 program).

Presenter of 1 Presentation

Resilience Factors Preventing Schizophrenia in Ultra-high Risk Patients: Lessons from Genetics

Session Type
European
Date
Sun, 05.06.2022
Session Time
17:00 - 18:30
Room
Hall C
Session Icon
Fully Live
Lecture Time
17:34 - 17:51

Abstract

Abstract Body

Over the past decades, researchers and psychiatrists in the field of psychosis have moved from a conception of a chronic presentation to a more dynamic paradigm. Accordingly, schizophrenia is now conceptualized as a progressive illness that typically emerges during late adolescence and follows different stages: early vulnerability, ultra-high risk state, first episode of psychosis, and chronic disease. Only one-quarter of the ultra-high risk patients will convert to a full-blown psychotic episode within 3 years while the others, called non-converters, will remain at-risk, develop other psychiatric disorders, or fully recover. The reasons for this differential outcome are not yet understood but this concept opens the way to scientific research to determine the protective factors involved in resilience for non-converters. Based on the Gene X Environment interaction model, schizophrenia results from genetic vulnerability and environmental aggressions which can have an impact on the epigenome and gene expression. Recent studies have shown that genetic variants play a role in the resilience of psychosis. Polygenic risk scores, computed as the addition of genetic polymorphisms, can modulate the effects of genetic at-risk deletions (i.e. del22q11) that predispose to psychosis and may also influence the cognitive symptoms of ultra-high risk patients. Resilience, defined as the ability to withstand adversity, is not only related to external skills or psychotherapeutic care but could also be explained by internal molecular factors. Identifying the genetic factors of resilience might help to stratify the risk and to develop precision medicine in psychiatry.

Hide